Enliven Therapeutics (ELVN) Projected to Post Earnings on Thursday

Enliven Therapeutics (NASDAQ:ELVN) is projected to announce its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $0.0080 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 3, 2026 at 3:00 PM ET.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). On average, analysts expect Enliven Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Enliven Therapeutics Stock Performance

ELVN stock opened at $30.24 on Wednesday. The firm has a 50 day simple moving average of $25.88 and a 200 day simple moving average of $22.02. Enliven Therapeutics has a 52 week low of $13.30 and a 52 week high of $30.78. The stock has a market cap of $1.81 billion, a P/E ratio of -16.26 and a beta of 0.33.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen lowered Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Enliven Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $41.00.

Insider Buying and Selling at Enliven Therapeutics

In other news, CFO Benjamin Hohl sold 10,000 shares of the firm’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $29.58, for a total transaction of $295,800.00. Following the transaction, the chief financial officer owned 51,000 shares in the company, valued at approximately $1,508,580. This trade represents a 16.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Anish Patel sold 48,300 shares of Enliven Therapeutics stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.99, for a total transaction of $1,351,917.00. Following the completion of the sale, the chief operating officer directly owned 215,011 shares of the company’s stock, valued at approximately $6,018,157.89. The trade was a 18.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 237,180 shares of company stock worth $6,301,233 over the last quarter. Company insiders own 25.90% of the company’s stock.

Institutional Trading of Enliven Therapeutics

Several large investors have recently made changes to their positions in ELVN. BNP Paribas Financial Markets increased its holdings in shares of Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after acquiring an additional 930 shares during the last quarter. Los Angeles Capital Management LLC bought a new stake in Enliven Therapeutics during the fourth quarter worth approximately $83,000. Quantbot Technologies LP boosted its position in Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares during the period. Tower Research Capital LLC TRC raised its position in shares of Enliven Therapeutics by 194.3% in the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock valued at $106,000 after purchasing an additional 3,490 shares during the period. Finally, Fox Run Management L.L.C. bought a new position in shares of Enliven Therapeutics in the fourth quarter worth about $191,000. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.